Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NiKem Research has received authorisation to perform acute and sub-chronic toxicology studies (upto 28 days) in all rodent species for preliminary safety evaluation of novel chemical entities (NCEs) from the Italian Ministry of Health, on March 29, 2010.
Subscribe to our email newsletter
NiKem Research said that Toxicokinetic (TK) studies are allowed to correlate plasma and/or organ exposure of NCEs (and metabolites) to tolerated doses in toxicology studies.
NiKem Research has provided preclinical support through its in-vitro ADME and in-vivo PK platform not only for numerous drug discovery programs but also as a standalone capability. The availability of acute and sub-chronic toxicology assessment represents a further development in NiKem’s preclinical services.
Giuseppe Giardina, CEO and managing director of NiKem Research, said: “The capability to introduce toxicology studies to the set of services being offered to our clients is a crucial step in the continuing expansion of our preclinical development services; our clients are delighted to fully exploit the one-stop-shop model and perceive this addition as a value for their outsourced drug discovery projects.”